Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neoagarotetraose (NAT) is a marine-derived oligosaccharide, specifically a tetrasaccharide produced by the enzymatic hydrolysis of agarose using β-agarase. It is primarily investigated for its prebiotic properties and its ability to modulate the gut-microbiota-metabolism axis. Preclinical research in ApoE−/− mice has demonstrated that NAT can significantly alleviate atherosclerosis by regulating cholesterol and bile acid metabolism through the modulation of gut microbiota composition. Additionally, NAT has shown potential in reducing high-fat diet-induced obesity via white adipocyte browning, extending lifespan in model organisms like *Caenorhabditis elegans* through AMPK-mediated signaling and autophagy activation, and protecting against exercise-induced fatigue and brain aging.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on neoagarotetraose.